IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.6% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 9,002 shares of the medical research company’s stock after selling 745 shares during the period. Wilmington Savings Fund Society FSB’s holdings in IQVIA were worth $1,769,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of IQV. Generate Investment Management Ltd purchased a new stake in IQVIA during the fourth quarter worth $8,262,000. Graphene Investments SAS boosted its stake in shares of IQVIA by 22.0% during the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock worth $2,948,000 after acquiring an additional 2,700 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its position in shares of IQVIA by 2.6% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,049,912 shares of the medical research company’s stock valued at $206,318,000 after acquiring an additional 26,648 shares during the period. Silver Oak Securities Incorporated increased its stake in shares of IQVIA by 18.0% in the 4th quarter. Silver Oak Securities Incorporated now owns 2,380 shares of the medical research company’s stock valued at $470,000 after purchasing an additional 363 shares in the last quarter. Finally, Bleakley Financial Group LLC raised its holdings in IQVIA by 40.7% in the 4th quarter. Bleakley Financial Group LLC now owns 7,881 shares of the medical research company’s stock worth $1,549,000 after purchasing an additional 2,281 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 0.9 %

NYSE:IQV opened at $208.13 on Monday. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock’s fifty day moving average is $200.67 and its two-hundred day moving average is $219.40. The stock has a market capitalization of $37.78 billion, a price-to-earnings ratio of 27.75, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts anticipate that IQVIA Holdings Inc. will post 10.81 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on IQV shares. Leerink Partners reiterated an “outperform” rating and issued a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. TD Cowen reduced their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Morgan Stanley lowered their price target on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research note on Wednesday, December 11th. Finally, Redburn Atlantic began coverage on IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 price target for the company. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $252.39.

Insider Buying and Selling

In other news, Director John G. Danhakl purchased 1,275 shares of the stock in a transaction on Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the acquisition, the director now directly owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.60% of the stock is owned by insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.